| 000 | 01808 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250515122753.0 | ||
| 264 | 0 | _c20080722 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a1537-162X | ||
| 024 | 7 |
_a10.1097/wnf.0b013e3181571a8e _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLugaresi, Alessandra | |
| 245 | 0 | 0 |
_aSafety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. _h[electronic resource] |
| 260 |
_bClinical neuropharmacology _c |
||
| 300 |
_a167-72 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study | ||
| 650 | 0 | 4 |
_aAdjuvants, Immunologic _xtherapeutic use |
| 650 | 0 | 4 | _aDisability Evaluation |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 | _aInterferon beta-1a |
| 650 | 0 | 4 |
_aInterferon-beta _xtherapeutic use |
| 650 | 0 | 4 |
_aMultiple Sclerosis, Relapsing-Remitting _xdiagnosis |
| 650 | 0 | 4 | _aPatient Satisfaction |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 |
_aSelf Administration _xinstrumentation |
| 650 | 0 | 4 | _aSeverity of Illness Index |
| 650 | 0 | 4 | _aSurveys and Questionnaires |
| 650 | 0 | 4 | _aSyringes |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aDurastanti, Valentina | |
| 700 | 1 | _aGasperini, Claudio | |
| 700 | 1 | _aLai, Marina | |
| 700 | 1 | _aPozzilli, Carlo | |
| 700 | 1 | _aOrefice, Giuseppe | |
| 700 | 1 | _aSotgiu, Stefano | |
| 700 | 1 | _aPucci, Emilio | |
| 700 | 1 | _aArdito, Bruno | |
| 700 | 1 | _aMillefiorini, Enrico | |
| 773 | 0 |
_tClinical neuropharmacology _gvol. 31 _gno. 3 _gp. 167-72 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/wnf.0b013e3181571a8e _zAvailable from publisher's website |
| 999 |
_c18013729 _d18013729 |
||